NEW YORK, Aug. 27, 2019 /PRNewswire/ -- Rob Gronkowski, three-time professional football champion with several records to his name, today announced that he has become an advocate for CBD and an investor in Abacus Health Products (CSE: ABCS)(OTCQX: ABAHF) ("Abacus" or the "Company"). Abacus is the maker of CBDMEDIC, the first family of all-natural topical medications that combine over the counter (OTC) drug active ingredients with CBD-rich hemp oil and other natural moisturizers. As part of the agreement, Gronkowski will partner with Abacus to expand CBDMEDIC's product line, with new recovery solutions planned for 2020.
Rob Gronkowski Becomes an Advocate for CBD And Partners with Abacus Health Products, Maker of CBDMEDIC
"I'm excited to start a new chapter of my career as an advocate for recovery and an investor and partner with Abacus — a company that I truly believe in," Gronkowski said. "During my football career, I pushed myself while recovering from nine surgeries and countless injuries. I was in near constant pain and needed to make a change. After retiring, I looked for better and more natural ways to recover and discovered CBDMEDIC through my dad. These products have helped me safely manage pain better than anything else I've tried. There is an incredible opportunity to educate people on healthier ways to recover and I'm looking forward to introducing new products with Abacus in the hope of helping millions of Americans balance their active lifestyles with healthy recovery."
Together with Abacus, Gronkowski will launch a complementary health and wellness line of CBD products in early 2020. These CBD products will be developed with Gronkowski's first-hand insights on pain management and recovery combined with Abacus's 15 years of pharmaceutical experience specializing in natural solutions. The new Gronk-inspired products will continue to meet the high quality standards of Abacus—using U.S. sourced broad-spectrum, CBD-rich hemp oil that does not contain THC, and therefore, is not psychoactive.
"We're proud to partner with one of the NFL's greatest tight ends of all time," said Abacus CEO Perry Antelman. "Gronk's passion for living life to the fullest while maintaining a healthy, natural, and pain-free lifestyle aligns perfectly with the mission of our company. Abacus is focused on providing safe, natural, and effective relief for millions of Americans in need of recovery."
CBDMEDIC's products includes 10 OTC topical pain relief medications for muscle and joint pain, back and neck pain, and arthritis-related pain, stiffness and swelling. These products are available for purchase online and at retail locations across the U.S., including CVS and Bed, Bath, and Beyond.
To learn more, purchase product, or find a retail location near you, visit www.cbd-medic.com.
About Abacus Health Products
Abacus is a company engaged in the development and commercialization of all natural over-the-counter (OTC) registered topical medications with active OTC drug ingredients combined with cannabinoid-rich hemp oil containing CBD from the cannabis sativa L plant. Abacus' products are aimed at the rapidly growing markets for topical pain relief and therapeutic skincare and are based on proprietary, patent-pending technologies developed by Abacus. Abacus's formulations combine advanced science with organic and natural ingredients to provide safe and effective relief. Abacus currently offers two lines of products: (i) CBD CLINIC™, marketed to the professional practitioner market, and (ii) CBDMEDIC™, marketed to the consumer market. Abacus' products are offered across the United States and are produced in the U.S. by a contract manufacturer in a cGMP compliant and audited manufacturing facility.
Launched in 2019, CBDMEDIC offers a line of topical pain medications that combine naturally-derived pain-relieving active OTC drug ingredients with 100% natural emollients (skin softening ingredients), essential oils, and broad spectrum THC-free, CBD-rich hemp oil to create unique formulations that work with the body for fast, effective, and targeted pain relief.
This news release contains forward-looking statements or information (collectively, "forward-looking statements") within the meaning of applicable securities legislation. Forward-looking statements are based on a number of assumptions and are subject to a number of risks and uncertainties, many of which are beyond the Company's control, that could cause actual results and events to differ materially from those that are disclosed in or implied by such forward-looking statements. Forward-looking statements contained in this news release include, without limitation, statements pertaining to the launch of new products, the proposed distribution and sales channels of the Company, and the execution of the Company's growth strategy.
The forward-looking statements contained in this news release are based on management's current expectations and are subject to a number of risks, uncertainties and assumptions, including assumptions regarding the Company's ability to efficiently operate its business, market and economic conditions, business prospects or opportunities, future plans and strategies, anticipated events and trends, and regulatory changes that may affect the Company and its customers and industry. There can be no assurance that actual results will not differ materially from those expressed or implied in forward-looking statements. Undue reliance should not be placed on forward-looking statements. Additional information about these risks, uncertainties and assumptions is contained under "Risk Factors" in the Company's listing statement – Form 2A dated January 29, 2019, which is available under the Company's SEDAR profile at www.sedar.com. Each forward-looking statement speaks only as of the date hereof, and the Company undertakes no obligation to correct or update any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by applicable law.
Neither the Canadian Securities Exchange (operated by CNSX Markets Inc.) nor its Regulation Service Provider accepts responsibility for the adequacy or accuracy of this release.
SOURCE: Abacus Health Products